Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

Area of Science:

• Pulmonology
• Respiratory Medicine
• Clinical Pharmacology

Background:

• Current guidelines recommend inhaled corticosteroids (ICS) for a select group of chronic obstructive pulmonary disease (COPD) patients.
• These patients typically have reduced lung function (Forced Expiratory Volume in 1 second [FEV1] <60%) and frequent exacerbations.
• The efficacy of ICS in COPD is supported by evidence showing reduced exacerbations, improved lung function, and enhanced quality of life in eligible patients.

Purpose of the Study:

• To critically review the existing evidence regarding the use of ICS in COPD.
• To explore the arguments for and against ICS administration in different COPD patient subgroups.
• To highlight the importance of recognizing COPD heterogeneity in clinical decision-making regarding ICS therapy.

Main Methods:

• Comprehensive literature review of studies investigating ICS use in COPD.
• Analysis of evidence pertaining to ICS efficacy in specific COPD phenotypes.
• Evaluation of data supporting or contradicting the benefits of ICS in COPD management.

Main Results:

• The available literature presents conflicting interpretations regarding the benefits of ICS in COPD.
• COPD is recognized as a heterogeneous condition, implying varied responses to ICS treatment.
• Evidence suggests ICS can be beneficial for exacerbation reduction and functional improvement in carefully selected COPD patients.

Conclusions:

• Clinicians must acknowledge COPD heterogeneity when considering ICS therapy.
• A nuanced understanding of ICS effects within specific COPD subgroups is crucial for effective treatment.
• Further research may be needed to refine ICS prescribing guidelines for the diverse COPD population.